ESC 2017
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
News
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
News
Researchers find oxygen therapy does not improve quality of life, forestall hospitalization, lengthen lives
News
The researchers found that 12% of infants in the high-flow group received escalation of care due to treatment failure versus 23% in the standard-therapy group.
News
Related death toll has also risen to 34 fatalities, spread across 24 states
Drugs in the Pipeline
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
News
US Centers for Disease Control and Prevention also reports 12 confirmed deaths in 10 states.